Physician profile
Timothy J Sullivan
NPI 1023012911
$6,773.90
in general payments reported to CMS, 2019-2025
30 companies · $973 in 2025
The $973 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $836 · 2021: $1,036 · 2022: $1,037 · 2023: $827 · 2024: $1,159 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,862 · Education: $97.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,861.58 |
| Education | $97.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,749.65 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $906.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $611.85 | 2019-2025 | |
| Csl Behring | $448.59 | 2020-2025 | Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $382.73 | 2020-2025 | Cuvitru, Hyqvia, Eohilia |
| Kaleo, INC. | $277.99 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $251.24 | 2019-2024 | Prolastin-C Liquid, Xembify |
| Amgen INC. | $246.31 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $236.03 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $221.01 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $203.53 | 2019-2023 | Ruconest |
| Optinose US, INC. | $203.08 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $167.29 | 2019-2022 | |
| Genentech USA, INC. | $113.14 | 2022-2023 | Xolair |
| Biocryst US Sales Co., LLC | $112.14 | 2022-2025 | Orladeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xoran Technologies LLC | $105.09 | 2020 | |
| Octapharma USA, INC. | $84.66 | 2019-2021 | |
| Pfizer INC. | $73.38 | 2019-2025 | |
| Shire North American Group INC | $61.31 | 2019 | |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Cycle Pharmaceuticals INC | $51.91 | 2025 | Sajazir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.94 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $31.87 | 2023-2024 | Voquezna |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $22.95 | 2025 | Neffy |
| Lilly USA, LLC | $21.00 | 2025 | Ebglyss |
| Horizon Therapeutics Plc | $18.07 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.81 | 2025 | Alvesco |
| Abbvie INC. | $14.75 | 2022 | |
| Lucid Diagnostics INC. | $13.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.